Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.

Kristen M Marks,Minhee Kang,Triin Umbleja,Anchalee Avihingsanon,Patcharaphan Sugandhavesa,Andrea L Cox,Karen Vigil,Hugo Perazzo,Jennifer C Price,Leolin Katsidzira,Christina Vernon, Beverly Alston-Smith,Kenneth E Sherman,

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 0|浏览5

暂无评分

摘要

In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要